MYL:NSD-Mylan N.V (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.08

Change

0.00 (0.00)%

Market Cap

USD 8.59B

Volume

1.99M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

+0.17 (+0.51%)

USD12.55B N/A N/A
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

+1.19 (+9.58%)

USD3.96B 41.54 454.68
CRON Cronos Group Inc

+0.16 (+1.46%)

USD3.93B 38.08 N/A
PCRX Pacira BioSciences, Inc

+0.17 (+0.23%)

USD3.20B 25.14 65.69
TLRY Tilray, Inc

+0.39 (+1.98%)

USD3.12B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.05 (-0.45%)

USD1.77B 15.78 14.06
ENDP Endo International plc

-0.06 (-0.84%)

USD1.64B N/A 9.98
SUPN Supernus Pharmaceuticals, Inc

+0.53 (+1.81%)

USD1.54B 12.12 7.71
ORGO Organogenesis Holdings Inc

-0.01 (-0.11%)

USD1.21B 456.50 77.95

ETFs Containing MYL

Symbol Name Weight Mer Price(Change) Market Cap
GNRX VanEck Vectors Generic Dr.. 0.00 % 0.55 %

N/A

USD3.35M
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+2.28 (+1.24%)

USD0.36B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -99.64% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.64% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -99.85% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.85% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -22.00% N/A N/A 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.00% N/A N/A 10% F
Risk Return Profile  
Volatility (Standard Deviation) 25.47% N/A N/A 70% C-
Risk Adjusted Return -86.35% N/A N/A 4% F
Market Capitalization 8.59B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.73 N/A N/A N/A N/A
Price/Book Ratio 1.64 N/A N/A N/A N/A
Price / Cash Flow Ratio 4.76 N/A N/A N/A N/A
EV/EBITDA 11.86 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 1.73% N/A N/A N/A N/A
Return on Assets 3.63% N/A N/A N/A N/A
Debt to Equity Ratio 94.37% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.15 N/A N/A N/A N/A
Short Percent 11.05% N/A N/A N/A N/A
Beta 1.47 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike